Innate Pharma (IPHA) Revenue (2019 - 2025)

Innate Pharma (IPHA) has reported Revenue for 7 consecutive years, with $3.2 million the latest figure, recorded in Q4 2025.

• Quarterly Revenue fell 77.92% year-over-year to $3.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $86.0 million (down 30.1% YoY) and the FY2025 annual result came in at $10.2 million, down 55.25% from the prior year.
• Revenue eased to $3.2 million in Q4 2025 per IPHA's latest filing, from $14.4 million in the prior quarter.
• Over the last five years, Revenue for IPHA reached as high as $56.4 billion in Q4 2022 and fell as low as $3.2 million in Q4 2025.
• A 5-year average of $7.1 billion and a median of $17.1 million in 2022 frame the typical range for Revenue.
• Annual changes were most pronounced in 2022 — Revenue jumped 409246.1% — and 2023, when it sank 99.9%.
• Year by year, Revenue stood at $13.8 million in 2021, then soared by 409246.1% to $56.4 billion in 2022, then plunged by 99.9% to $59.1 million in 2023, then sank by 75.68% to $14.4 million in 2024, then sank by 77.92% to $3.2 million in 2025.
• According to Business Quant data, Revenue over the past three periods registered $3.2 million, $14.4 million, and $9.4 million for Q4 2025, Q4 2024, and Q2 2024 respectively.